Inflammatory responses are critical for survival; however, aberrant inflammation is implicated in a variety of neurodegenerative, cardiovascular, autoimmune, and metabolic diseases.
The central nervous system (CNS) has a separate immune state to the rest of the body, initiating its own neuro-inflammatory response via microglia. Due to the CNS’s poor repair mechanisms, immune responses must be terminated to maintain homeostasis. Persistent insult, or inadequate termination, leads to chronic neuroinflammation, a continuous and self-exacerbating cycle.
Chronic neuroinflammation has been identified as a driving force in many brain pathologies including dementias, traumatic brain injury and stroke. Drugs that inhibit abnormal inflammatory responses (e.g. nucleotide-binding oligomerization domain-like receptors family pyrin domain containing 3 (NLRP3) inflammasome inhibitors) have thus become highly sought after, due to their potential to modulate multiple disease-states.
Domainex has a team of highly skilled scientists with world-class knowledge and experience in drug discovery for inflammatory conditions, including neurodegenerative and neuroinflammatory disorders. Our scientists have a wide range of experience and expertise and employ in house state-of-the-art technologies to solve complex research challenges. We have developed a comprehensive suite of assays to enable the profiling and development of novel compounds targeting inflammatory and neuroinflammatory targets.